No dosing recommendations available. Not recommended for HIV-positive children beginning anti-HIV drug treatment for the first time. Is effective in children who have used other protease inhibitors in the past, when combined with low-dose Norvir (ritonavir).
No dosing recommendations available.
A liquid solution of Agenerase is available for babies and children.
There is no official Crixivan dose for use in children. The correct dose of Crixivan—if it is approved by the U.S. Food and Drug Administration—will depend on the size of the child. The dose currently being explored in clinical trials is 500 mg per square meter of body surface area, every eight hours. Children with small body surface areas may require lower doses of the drug.
Children between the ages of 6 months and 18 years receive dosing based on either body size or body weight and depends on other HIV medications being used (Lexiva [fosamprenavir], Sustiva [efavirenz], Viracept [nelfinavir] or Viramune [nevirapine]). Although once-daily dosing is available for adults, only twice-daily dosing should be used for children.
Kaletra can be used by infants who are between 14 days and 6 months of age. It should only be used twice a day and the dose will depend on the child's body size or body weight. It should not be combined with Lexiva, Sustiva, Viracept or Viramune in children younger than six months of age.
A liquid formulation of Kaletra—containing 42.4 percent alcohol—is available for babies and children, which is easier to give to young children than the adult capsules.
Lexiva is only approved for children 2 years of age or older. Once-daily Lexiva, an option for adults, is not recommended for children (even if it is used with Norvir). There are three dosing options for children, depending on their body weight and age. Children between 2 and 5 years of age should take 30 mg of liquid Lexiva per kilogram of body weight twice daily. This option is only for 2- to 5-year-olds starting HIV treatment for the first time (treatment naive), and combining Lexiva with Norvir is not recommended. For treatment-naive children 6 years of age or older, the dose is 30 mg per kilogram of body weight twice daily, or 18 mg per kilogram of liquid Lexiva plus 3 mg per kilogram of liquid Norvir twice daily. For treatment-experienced children 6 years of age or older, the dose is 18 mg per kilogram of Lexiva plus 3 mg per kilogram of Norvir twice daily.
No dosing recommendations available.
A liquid formulation of Lexiva is available for children two years of age and older.
Norvir is mostly used to boost the blood levels of other protease inhibitors. Low doses of the drug are used for this purpose. Norvir is rarely, if ever, used at its full dose to treatment HIV-positive children or adults. The Norvir dose prescribed with depend on the protease inhibitor it is being combined with, as well as the child's body size or body weight.
Infants older than 1 month of age can take Norvir, using the dosing schedule recommended for children or the dosing specified using other protease inhibitors.
A liquid formulation of Norvir is available for babies and children, which is easier to give to young children than the adult capsules.
Only for children 6 years of age and older. Dosing is based on the child's body weight. For children between 20 and 29 kilograms (44 and 65 pounds), the dose should be five 75 mg tablets (375 mg) plus 50 mg of liquid Norvir (ritonavir), twice a day. For children between 30 and 39 kg (66 and 87 pounds), the dose should be six 75 mg tablets (450 mg) plus 60 mg of liquid Norvir, twice a day. For children weighing more than 40 kg (88 pounds), the adult dose is recommended: one 600 mg tablet plus one 100 mg Norvir capsule, twice a day. Once-daily Prezista, an option for adults starting HIV therapy for the first time, is not an option for HIV-positive children.
Only for children six years of age older. The dose of Reyataz, which should always be taken with food, will depends on the child's body weight. For children starting HIV treatment for the first time and weighing between 15 and 24 kilograms (33 and 54 pounds), the dose is one 150 mg capsule of Reyataz with 80 mg of liquid Norvir (ritonavir) once daily. For children between 25 and 31 kilograms (55 and 69 pounds), the dose is one 200 mg capsule of Reyataz and 100mg of Norvir (liquid or capsule) once daily. For all children between 32 and 38 kilograms (70 and 85 pounds), the dose is one 250 mg capsule of Reyataz and 100mg of Norvir once daily. For children 39 kilograms (86 pounds) and heavier, the dose is one 300 mg capsule of Reyataz with 100 mg of Norvir once daily. For children who are at least 13 years old and at least 39 kilograms (86 pounds), but who can't tolerate Norvir, the appropriate dose is 400 mg of Reyataz (without Norvir), once daily, with food.
No dosing recommendations are available for children under 6 years of age. Children under the age of 3 months should never receive Reyataz due to the risk of brain damage from excess bilirubin blood levels.
Reyataz is available in 150, 200, 250 and 300 mg capsules.
Viracept is only approved for children 2 years of age and older. The approved dose for children 2 years of age and older is 45 to 55 mg per kilogram of body weight, twice a day, or 25 to 35 mg per kilogram of body weight three times a day. Viracept should be taken with a meal.
No dosing recommendations available.
Viracept is available in a powder that can be mixed with liquid. Each gram—one level scoop—of Viracept powder contains 50 mg of the drug.
Search for news stories about this topic